Definitive Contract 75F40125C00069
Award Date
9/11/25
Potential Completion Date
3/29/30
Potential Value
$1.1M
Federal Agency
Food and Drug Administration
Awardee
Genentech Inc.
Ultimate Awardee
Not listed
PSC Category
AJ11 - General Science And Technology R&D Services; General Science And Technology; Basic Research
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Food and Drug Administration (FDA) awarded a $515,769.89 firm fixed price definitive contract to the University of St. Gallen, a Swiss educational institution, to conduct research and develop tools to strengthen post-market surveillance of FDA-regulated products. The objective is to apply advanced analytics and hybrid artificial intelligence to improve risk identification. This contract was awarded under the FDA's Fiscal Year 2025 Broad Agency Announcement (BAA) for Advanced Research...
This is a $1,904,355.00 definitive cost-no-fee contract awarded by the Food and Drug Administration (FDA), a civilian government agency, to the Institute Of Quantitative Systems Pharmacology, a non-profit organization. The contract is for basic and applied research with two key objectives: (1) to test the hypothesis that variabilities in nanoparticle (NP) properties and tumor targets cause uncertainties in "FORMULA", and (2) to develop computational models to predict the...
This federal contract was awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to the Universitat ST. Gallen, doing business as Hochschule FÜR Wirtschafts-, Rechts- UND Sozialwissenschaften (Hsg), an educational institution. The contract is a Firm Fixed Price definitive contract with a potential value of $764,418.19 and a completion date of September 29, 2023. The contract was awarded under the FDA's Broad Agency Announcement (BAA) for Advanced Regulatory...
This is a $978,324 definitive contract awarded by the Food and Drug Administration (FDA) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for a 2-year period ending in April 2025. The contract is to enhance the FDA's Source Model by incorporating and analyzing state and regional-level data. The contract was awarded under a Broad Agency Announcement (BAA) that solicits advanced research and development proposals to support FDA regulatory science...
This is a $5,000,001.00 definitive contract awarded by the Food and Drug Administration (FDA) to the Massachusetts Institute of Technology (MIT) for "APPLICATION OF SMART DATA ANALYTICS FOR BIOMANUFACTURING." The contract has no set-aside designation and is a cost-type contract without fee. The contract was awarded under the FDA's Broad Agency Announcement for Advanced Regulatory Science, which solicits research and development proposals across various regulatory science areas to...
This is a $699,087 firm-fixed price definitive contract awarded by the Food and Drug Administration (FDA) to Duke University, a prestigious private research institution located in Durham, North Carolina. The contract is for basic and applied research and development to support regulatory science and innovation, in alignment with the FDA's mission to protect and promote public health. This award is part of the FDA's agency-wide Broad Agency Announcement (BAA) for research and development. The...
This is a definitive contract awarded by the Department of Health and Human Services Food and Drug Administration to Georgia Tech Research Corporation, a non-profit research organization and state institution of higher education. The contract, valued at $1,470,387.82, is for the identification of critical quality attributes of cell therapy products through multi-omics analyses and predictive modeling. The contract was awarded on September 30, 2020 and has a completion date of September 29, 2024....
This is a $723,710.98 firm-fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Eurofins Discovery Services North America, LLC, a foreign-owned for-profit contract research organization. The contract is for non-clinical and laboratory support services and has a period of performance through September 2028. The contract is not associated with a specific set-aside program. Eurofins Discovery Services North America, LLC holds several multi-million dollar...
The U.S. Food and Drug Administration (FDA) awarded a $1,155,442.55 Cost Plus Fixed Fee contract to Cubrc, Inc. to conduct research and development on the "Immunogenicity Risk of Peptide Drug Generics and Their Impurities: In Silico and In Vitro Assessment and Validation Methods." The contract, which has a period of performance ending September 27, 2022, was issued under the FDA's Broad Agency Announcement (BAA) solicitation for advanced research and development to support regulatory...
This definitive, firm fixed-price contract was awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to CFD Research Corporation, a for-profit organization, to develop a multiscale computational framework for assessing the bioequivalence of orally inhaled drugs. The $499,761 contract does not have a set-aside designation. The original solicitation was a Broad Agency Announcement (BAA) seeking research and development to advance FDA's mission of protecting...